MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 65.0% from a year ago
Other current liabilities stood at $11.15M at the end of Q1 FY2026, up 65.0% from a year earlier and up 21.5% from the prior quarter. Over 3 fiscal years it compounded at +89.8% a year.
Context
- Other current liabilities amounted to 2.7% of total assets at the end of Q1 FY2026, down 3.4 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +65.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 9.18M USD
- Year-over-year change
- +53.5%
- 3-year CAGR
- +89.8%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.18M | +53.5% |
| FY2024 | 2024-12-31 | 5.98M | +49.6% |
| FY2023 | 2023-12-31 | 4M | +197.8% |
| FY2022 | 2022-12-31 | 1.34M | — |
Other Current Liabilities vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 other current liabilities of $11.15M is the 5th highest of the 11 companies compared; the peer median is $6.93M.
- Its year-over-year change of +65.0% is the 3rd highest of 8, against a peer median of +29.9%.
- Other current liabilities amounts to 2.7% of total assets for MPLT, versus a peer median of 2.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.96B | +450133.7% | — | 4.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $24.77M | +294.3% | +42.0% | 16.1% |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $21.33M | -53.2% | +67.6% | 2.0% |
| Mar 2026 | $14.58M | -44.7% | +215.9% | 5.2% | |
| Mar 2026 | $11.15M | +65.0% | +89.8% | 2.7% | |
| Mar 2026 | $7.61M | — | +35.8% | 2.8% | |
| Mar 2026 | $6.25M | +29.9% | +9.3% | 2.3% | |
| Mar 2026 | $5.41M | — | — | 2.4% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $3.08M | +46.6% | — | 0.6% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $1.97M | — | +136.0% | 0.5% |
| Dec 2025 | $1.7M | -15.9% | — | 1.3% | |
| Peer median (excluding MPLT) | $6.93M | +29.9% | +54.8% | 2.3% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.